A Simple LC-MS/MS Method for Determination of Vemurafenib in Rat Plasma Fed with High Fat Diet

Ayşe Özdemir¹, Senem Şanlı²* and Erten Akbel³

¹Division of Biochemistry, School of Medicine, Uşak University, Uşak, Turkey.
²Department of Chemistry, Faculty of Science and Arts, Uşak University, Uşak, Turkey.
³Department Physiotherapy and Rehabilitation, Faculty of Health Sciences, Uşak University, Uşak, Turkey.

Authors’ contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i40B32285

Editor(s):
(1) Dr. Dharmesh Chandra Sharma, G. R. Medical College & J. A. Hospital, India.
(2) Hamza Ahmed Pantami, Gombe State University, Nigeria.
(3) Zhipeng Li, Guangxi University, China.
(3) Younus Khudhur, Kirkuk University, Iraq.

Complete Peer review History: https://www.sdiarticle4.com/review-history/70681

Received 25 May 2021
Accepted 30 July 2021
Published 12 August 2021

Original Research Article

ABSTRACT

In this study, high fat diet was fed to rats and the amount of vemurafenib in rat plasma was determined by the developed liquid chromatography with tandem mass spectrometry. The calibration curve was linear between 0.01 and 0.8 µg mL⁻¹ vemurafenib with 0.999 regression coefficient. The limit of detection and quantification of the method are estimated from the signal to noise ratio 3:1 and 10:1, respectively. These are 1.10⁻⁴ µg mL⁻¹ for LOD and 4. 10⁻⁴ µg mL⁻¹ for LOQ. This method has been found to be reproducible and highly sensitive and provides a combination of faster analysis time and improved limits of detection.

Keywords: Vemurafenib; rat plasma; LC-MS/MS; fat diet.

1. INTRODUCTION

Vemurafenib (VEM, Fig. 1) is the first selective, potent and orally bioavailable inhibitor of the serine/threonine-protein kinase b-raf protein encoded by the V600E mutated braf gene [1]. Vemurafenib was recently approved by authorized agencies for the treatment of
metastatic melanomas harboring BRAFV600E mutations [2]. A relationship between tumor size change and plasma exposure to VEM has been reported [3]. Mutation of the braf gene is very common in melanoma [4,5]. Recently, improved survival was observed in an ongoing Phase III clinical study with vemurafenib compared to dacarbazine in patients with previously untreated metastatic melanoma with this mutation [6]. Total metabolite levels in plasma were below 6% compared to the parent drug level [7]. To further improve survival of melanoma patients after a 40 years lack of progress, combination therapies will be explored, especially combinations with immunomodulators are expected to be very active [1].

The literature survey revealed that few liquid chromatography – tandem mass spectrometry (LC-MS/MS) methods have been reported for the analysis of vemurafenib in human and rat plasma [6-13].

The aim of the study, determination of vemurafenib amounts in rat plasma which fed with high fat diet by developed LC-MS/MS method. Also simple protein precipitation with acetonitrile could be done in order to quantify VEM in high fat diet rat plasma samples. The developed method is simpler, faster and cheaper than published methods using liquid-liquid extraction or solid phase extraction for sample preparation technique.

2. METHODOLOGY

2.1 Chemicals, Reagents and Animals

All chemicals were analytical reagent-grade. Vemurafenib was kindly donated by Roche Pharm. Ind. (Istanbul, Turkey). Acetonitrile (organic modifier) and dimethylsulfoxide (DMSO) and formic acid were purchased from Merck (Darmstadt, Germany). Milli-Q system (Millipore, Bedford, MA, USA) was used to get ultrapure water. Male Wistar Albino rats (2–3 months old; equal weight) were purchased from the animal breeding laboratories of Afyon Kocatepe University Experimental Animal Research and Application Center (Afyon, Turkey). All rats were housed under standard conditions of temperature (23°C ± 2°C), humidity, and 12-h dark–light cycle. The animals were fed standard rat feed supplied by Bil-Yem Ltd. (Turkey).

2.2 Equipment

For the analysis of the VEM using LC-MS/MS was carried out on Agilent 6460 triple quad mass spectrometer. This instrument was equipped with an electrospray ionisation (ESI), operating in positive mode and configured scan mode monitoring. All solutions were degassed by ultrasonication (Sonorex, Bandelin, Germany).

2.3 Solutions

2.3.1 Preparation of standards and stock solutions

The stock solution of VEM (1000 µg mL⁻¹) was prepared in DMSO and stored at +4 °C. The working solutions to spike plasma samples were diluted from the stock solution with acetonitrile. The calibration standards at six concentrations level (0.01 and 0.8 µg mL⁻¹) were prepared with spiking of the blank plasma samples with the working standard solutions. The blank plasma samples were stored at -20°C.

2.4 Animal Study

300-350 gram Wistar Albino rats were used for the study. These rats were acclimated to lab conditions for 7 days before being taken into the experimental process. The rats were feed high fat diet by three weeks. In order to provide a high fat diet as much as the rats’ nutritional needs, butter was melted and added according to the ratio of 25 grams of butter to 100 grams of standard diet (Mis Butter-MilkMan Milk and Milk Products. Food Industry and Trade Inc.). It was mixed with a mechanical stirrer to allow the oil to suck and then allowed to cool. High-fat diet prepared fresh daily. During the experiment, it was observed that the animals were in compliance with this diet.

After feeding with high-fat diet, VEM (10 mg/kg) was injected to rat and blood samples were collected after 12 hours. After completion of the experimental phase, the rats were treated with 87 mg / kgi.m. Preanaesthesia with xylazine administration was then performed at a dose of 13 mg / kgi.m. Ketamine was fully anesthetized. During the collection of plasma samples, after the anesthesia, the rib cage was opened and blood samples were taken intracardially with EDTA (Ethylenediamine tetra acetic acid) syringe for analysis. Immediately after this, cervical dislocation was performed and sacrifice was
Vemurafenib

N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-carbony]-2,4-difluorophenyl]propane-1-sulfonamide

CAS No: 918504-65-1

Fig 1. Chemical structure of vemurafenib

C_{23}H_{18}ClF_{2}N_{3}O_{3}S  MW : 489.9 g mol^{-1}

2.5 Preparation of Rat Plasma Samples for Analysis

The proteins in the 500 µl rat plasma samples were crashed with 1000 µl acetonitrile. After vortexing for 3 minutes, the samples were centrifuged at 15000 rpm for 10 min. Finally, 1000 µl solution was transferred to a clean vial ran on LC-MS/MS system.

2.6 Chromatographic Conditions

For plasma sample analysis, ACN-water (50/50 (v/v)) including % 0.1 (v/v) formic acid was used as a mobile phase. A Zorbax Eclipse plus C18 (2.1×50 mm ID ×1.8µ) column was used stationary phase. The column temperature was kept at 30 °C. Triple-quadrupole mass spectrometer with an electrospray ionization source has been used in positive mode. A mobile phase composed of ACN-water mixture containing 0.1% formic acid was used to attain good resolution, symmetrical peak shapes and shorter run time. Vemurafenib was monitored at m/z 490.0 → 383.0 and monitored at m/z 490.0 → 254.9. Table 1 summarizes the MS operating parameters.

3. RESULTS AND DISCUSSION

The calibration curves of vemurafenib were plotted peak areas of vemurafenib versus the spiked plasma concentrations at six levels (0.01, 0.05, 0.1, 0.2, 0.4 and 0.8 µg mL^{-1}). The calibration curve was linear between 0.01 and 0.8 µg mL^{-1} vemurafenib with 0.999 regression coefficient. The calibration curve equation is y = 626574x-1288, where x is the concentration and y is the peak area. LOD and LOQ of the method are estimated from the signal to noise ratio 3:1 and 10:1, respectively. These are 1.10^{-4} µg mL^{-1} for LOD and 4. 10^{-4} µg mL^{-1} for LOQ. Standard chromatogram of VEM was given in Fig. 2.

| Gas Temp (°C) | 325 |
|---------------|-----|
| Gas Flow (L/min) | 11 |
| Nebulizer (Psi) | 45 |
| Sheat gas heater (°C) | 400 |
| Sheat gas flow | 12 |
| Capillary (V) | 3000 |
| Vcharging | 500 |
| Parent mass (m/z) | 490 |
| Product mass (m/z) | 383 |
| Dwell time (ms) | 45 |
| Collision energy (V) | 30 |
| Retention time (min) | 1.150 |
| Fragmentor voltage | 160 |

Intra-day and inter-day analyses were utilized to investigate accuracy and precision of the developed method. Two different concentrations of vemurafenib (0.05 and 0.2 µg mL^{-1}) were analyzed six times in the same day and once in each day following to six consecutive days. The relative standard deviation (RSD) and the bias of intra- and inter-day studies were evaluated for accuracy and precision of the method (Table 2). The intra-day and inter-day results indicate that the developed method was accurate and precise.

The recovery of the developed method was investigated comparing the peak area obtained from spiked plasma samples with at same level
of working standard solutions (0.05 µg mL\(^{-1}\) vemurafenib). The recovery of vemurafenib from rat plasma samples was found to be 91.50% ± 0.60. The high recovery shows that the sample preparation step is efficient to retrieve VEM from plasma.

In the literature, when high-fat ketogenic diet (high fat, adequate protein and low carbohydrate) were given to xenograft rat, increase of serum acetoacetate levels and growing of human melanoma cells were observed [14]. In this study, in addition to the literature, the effects of high-fat diet on the amount of vemurafenib in rat plasma were investigated. In the literature, effects of high-fat diet on the rat plasma sample have not been investigated yet.

At the beginning of the study, the body weight of the rats was 345.9 ± 15.1 g and 358.1 ± 23.2 g after a 3-week high-fat diet. There was no statistical increase in the weight of rats despite high fat diet.

Rat plasma samples were collected 12 hours after injection of vemurafenib. Then, plasma samples were prepared as described in the ‘Preparation of plasma samples for analysis’. Typical chromatograms of rat plasma sample is shown in Fig. 3. There are no extraneous peaks in chromatograms obtained for plasma samples. The amount of VEM (after 12 hours injection of drug) in rat plasma samples was calculated as 8.73 ± 0.052 (n=6).

The use of chemotherapeutic drugs in borderline or malignant obesity patients is a issue that needs to be considered when the fatty diet changes the efficacy of cancer drugs. It is obvious that a condition that decreases or inhibits the effectiveness of VEM, an important survival agent, will interfere with treatment. In our study, when the calculated values were compared with the literature values [6], we can say that the fat diet does not change the blood levels of the drug or the blood level of the drug is not affected by the fat diet.

![Sample Chromatogram](image)

**Fig. 2. Chromatogram of VEM standard (0.01 µg mL\(^{-1}\))**

**Table 2. Summary of repeatability (intra-day) and reproducibility (inter-day) precision data for vemurafenib by LC-MS/MS**

| Compound concentration (µg.mL\(^{-1}\)) | Intra-day | Inter-day |
|----------------------------------------|-----------|-----------|
|                                        | Mean Recovery % ± RSD % | Mean Recovery % ± RSD % |
| 0.05                                   | 100.113 ± 0.638           | 100.027 ± 0.527          |
| 0.2                                    | 100.157 ± 0.514           | 99.998 ± 0.245           |

*Each value is obtained from six experiments (n=6)
Fig. 3. Chromatogram of rat plasma sample after injection of VEM 12 hours later

4. CONCLUSION

Although several methods have been reported for determination of VEM, to the best of our knowledge, there are no data for VEM about high-fat diet on the rat plasma sample yet. Although the studies on the changes in the blood levels of high-fat diet VEM are limited, our study is promising to shed light on the studies evaluating the effects on human health.

Also in this work, simple, fast and effective LC-MS/MS method has been applied to determine VEM for rat plasma samples. Also, this method has been found to be reproducible and highly sensitive and provides a combination of faster analysis time and improved limits of detection.

CONSENT

It is not applicable.

ETHICAL APPROVAL

The study protocol is approved by Animal Experimentation Local Ethics Board (No: AKUHAYDEK-38-16).

ACKNOWLEDGEMENTS

The authors are thankful for the financial aid received from the Scientific Research Projects Unit (BAP-2017/SB003) of Usak University.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Cantwell-Dorris ER, O'Leary JJ, Sheils OM. Mol. Cancer Ther. 2011;10:385.
2. Keating GM. Bio Drugs. 2012;26:325.
3. Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P. Nat. Rev. Drug Discov. 2012;11:873.
4. European Medicine Agency. Available: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002409/WC500124400.pdf, p. 35
5. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutatated activated BRAF in metastatic
melanoma, N. Engl. J. Med. 2010;363:809–819.
6. Sparidans RW, Durmus S, Schinkel AH, Schellens JH, Beijnen JH, Chromatogr J. B. Analyt. Technol. Biomed. Life. Sci. 2012;889–890:144.
7. Marine Rousseta, Karine Titiera, Stephane Boucheta, Caroline Dutriauxc, Anne Pham-Ledardc, Sorilla Preyc, et al. Clinica Chimica Acta. 2017;470:8–13.
8. Alvarez JC, Funck-Brentano E, Abe E, Etting I, Saiag P, Knapp A. A LC-MS/MS micro-method for human plasma quantification of vemurafenib. Application to treated melanoma patients. J. Pharm. Biomed. Anal. 2014;97:29–32.
9. Nijenhuis CM, Rosing H, Schellens JH, Beijnen JH. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying vemurafenib in human plasma. J. Pharm. Biomed. Anal. 2014;88:630–635.
10. Bihan K, Sauzay C, Goldwirt L, et al. Development and validation of a rapid and simple LC-MS/MS method for quantification of vemurafenib in human plasma: Application to a human pharmacokinetic study, Ther. Drug Monit. 2015;37(1):132–136.
11. Herbrink M, de Vries N, Rosing H, et al. Quantification of 11 therapeutic kinase inhibitors in human plasma for therapeutic drug monitoring using liquid chromatography coupled with tandem mass spectrometry, Ther. Drug Monit. 2016;38(6):649–656.
12. Vikingsson S, Stromqvist M, Svedberg A, Hansson J, Hoiom V, Green H. Novel rapid liquid chromatography tandem massspectrometry method for vemurafenib and metabolites in human plasma, including metabolite concentrations at steady state, Biomed. Chromatogr. 2016;30(8):1234–1239.
13. Zhi-ling Zhoua, Ji-feng Denga, Ying-jun Lic, Yu Changd, Hui-min Cheng Journal of Pharmaceutical and Biomedical Analysis. 2016;129:142–147.
14. Xia S, LinR, Jin L, Zhao L, KangH-B, Pan Y, et al. Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. Cell Metabolism. 2017;25(2):7,358-73.

© 2021 Özdemir et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle4.com/review-history/70681